NPX267

NPX267 · NextPoint Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NPX267, covering 2025-06-27 to 2025-06-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 [Phase 1]